Sanofi and Regeneron Report P-III Trial (PRIME) and (PRIME2) Results of Dupixent (dupilumab) for the Treatment of Prurigo Nodularis
Shots:
- The 2 P-III trials (PRIME) & (PRIME2) evaluating Dupixent in 311 adults, showed an improvement in itch from baseline (measured by a ≥4-point reduction in WI-NRS) @24 & 12wks, respectively
- Additional EPs incl. clear or almost clear skin of nodules @ 24wks. (measured by a score of 0 or 1 on IGA PN-S), improvement from baseline in health-related QoL, skin pain & symptoms of anxiety & depression. The safety results were consistent with the known safety profile of Dupixent in its approved dermatology indication
- The results were published in Nature Medicine. Dupixent received regulatory approvals in 1+ countries globally for AD, asthma, CRSwNP, EoE, or PN in different age populations
Ref: Sanofi | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
